Growing Interest in Potential of HIFU to Offer an Alternative Treatment for Prostate Cancer Designed to Balance Effectiveness and Quality of Life

Charlotte, N.C. – November 19, 2012 -- The ability for technology from USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies, to offer another treatment option for prostate cancer designed to balance treatment effectiveness and quality of life was the focus of several research studies presented recently at the Third International Symposium on Focused Ultrasound.  

Focal Therapy Using Sound Waves to Target Individual Areas of Cancer Shows Promise as Alternative to Traditional Treatments for Prostate Cancer

Charlotte, N.C. – April 17, 2012 -- A new treatment for prostate cancer using high intensity focused ultrasound (HIFU) to deliver focal treatment may provide an alternative to traditional treatment with significantly fewer side effects, according to results from a study published in the current issue of Lancet Oncology (DOI:10.1016/S1470-2045(12)70121-3). Incontinence and erectile dysfunction are common side effects of treatments for localized prostate cancer.

Medical Device Industry Veteran Michael Klein Brings 30 Years of Experience to US HIFU

CHARLOTTE, N.C., January 6, 2012 -- USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies,  appointed Michael Klein as the company's new chief executive officer and member of the board of directors. Mr. Klein brings more than  30  years of experience in oncology and the medical device industry to US HIFU, most recently as president of the radiation oncology division of  Roper Industries, Inc. (NYSE: ROP), a publicly traded, diversified manufacturer of engineered products. US HIFU is backed by an investor syndicate led by Galen Partners, a leading healthcare growth equity and late stage venture capital firm. 

Page 10 of 10

HIFU company

Latest News

03 July 2018

Sonablate® HIFU used in study to treat clinically significant nonmetastatic prostate cancer achieves complete pad-free urinary continence in 98% of men.

17 May 2018

SonaCare Medical congratulates Naren Sanghvi on his receipt of The William and Francis Fry Honorary Fellowship for Contributions to Therapeutic Ultrasound